Andrographolides
Primary Progressive Multiple Sclerosis
Innobioscience SpAPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Primary Progressive Multiple Sclerosis cohort.
View all 46 →
Same molecule, other indications
Andrographolides is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →